Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Supply, Demand and Key Producers, 2026-2032
Description
The global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market size is expected to reach $ 549 million by 2032, rising at a market growth of 3.2% CAGR during the forecast period (2026-2032).
Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine is a biological product designed to prevent and control PRRS, a highly contagious viral disease that affects pigs. The vaccine works by stimulating the pig's immune system to produce a protective response against the PRRS virus, thereby reducing reproductive failures such as abortions and stillbirths in sows, as well as respiratory illness and mortality in piglets and growing pigs. PRRS vaccines are typically classified into modified live vaccines (MLVs) and inactivated vaccines, and they play a critical role in improving herd health and productivity in the swine industry worldwide.
The global PRRS vaccine market is primarily driven by the widespread prevalence and economic impact of Porcine Reproductive and Respiratory Syndrome in the swine industry. PRRS is one of the most devastating diseases affecting pigs, causing significant reproductive losses in breeding herds and severe respiratory distress in growing pigs. The virus's ability to mutate and persist in herds has made it difficult to eradicate, leading to chronic infections and substantial financial losses for pig farmers. As a result, governments and veterinary authorities in major pork-producing countries such as China, the United States, and countries in the European Union have emphasized vaccination as a critical component of disease control programs. Additionally, rising global pork consumption is pressuring producers to maintain healthier herds and ensure consistent productivity, further boosting demand for effective PRRS vaccines. Technological advancements in vaccine formulation—such as the development of region-specific or genotype-specific modified live vaccines (MLVs)—have improved vaccine efficacy, making immunization a more reliable and widely accepted preventive measure. Moreover, increasing biosecurity awareness and the integration of vaccination into herd health management systems are reinforcing the growth of the PRRS vaccine market globally.
Despite its importance, the PRRS vaccine market faces several challenges that limit its effectiveness and adoption in certain regions. One of the primary issues is the virus's high genetic variability, which complicates the development of universally effective vaccines. The presence of multiple genotypes and frequent mutations means that vaccine strains may not provide cross-protection against all circulating variants, leading to inconsistent results and partial immunity in vaccinated herds. Additionally, modified live vaccines (MLVs), while generally more effective than inactivated ones, carry risks of reversion to virulence or recombination with field strains, which raises safety concerns among producers and regulatory bodies. In developing regions, limited access to veterinary services, cold chain logistics, and affordability issues further hinder the widespread adoption of PRRS vaccination programs. Moreover, there remains a lack of standardized vaccination protocols across countries, and vaccine performance can vary depending on farm conditions, pig genetics, and co-infections with other pathogens. These factors make disease management complex and can reduce confidence in vaccination strategies. Overcoming these challenges requires continued investment in research and development of next-generation vaccines, improved diagnostic tools for strain identification, and stronger government support for vaccination campaigns and swine health education.
This report studies the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine total production and demand, 2021-2032, (K Dose)
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine total production value, 2021-2032, (USD Million)
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine domestic production, consumption, key domestic manufacturers and share
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include China Animal Husbandry Co., Ltd., Boehringer Ingelheim, MSD Animal Health, Sinopharm Animal Health, Ceva, Ruipu Biological, Qilu Animal Health, Dahuanong, CAVAC, Komipharm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market, Segmentation by Type:
Live vaccines
Inactivated vaccines
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market, Segmentation by Application:
Government bidding
Market sales
Companies Profiled:
China Animal Husbandry Co., Ltd.
Boehringer Ingelheim
MSD Animal Health
Sinopharm Animal Health
Ceva
Ruipu Biological
Qilu Animal Health
Dahuanong
CAVAC
Komipharm
Agrovet
Bioveta
Jinyu
Phibro Animal Health
Tiankang
Zoetis
Yongshun Biological
Pulike Biological
Key Questions Answered:
1. How big is the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market?
2. What is the demand of the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market?
3. What is the year over year growth of the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market?
4. What is the production and production value of the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market?
5. Who are the key producers in the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market?
6. What are the growth factors driving the market demand?
Porcine Reproductive and Respiratory Syndrome (PRRS) vaccine is a biological product designed to prevent and control PRRS, a highly contagious viral disease that affects pigs. The vaccine works by stimulating the pig's immune system to produce a protective response against the PRRS virus, thereby reducing reproductive failures such as abortions and stillbirths in sows, as well as respiratory illness and mortality in piglets and growing pigs. PRRS vaccines are typically classified into modified live vaccines (MLVs) and inactivated vaccines, and they play a critical role in improving herd health and productivity in the swine industry worldwide.
The global PRRS vaccine market is primarily driven by the widespread prevalence and economic impact of Porcine Reproductive and Respiratory Syndrome in the swine industry. PRRS is one of the most devastating diseases affecting pigs, causing significant reproductive losses in breeding herds and severe respiratory distress in growing pigs. The virus's ability to mutate and persist in herds has made it difficult to eradicate, leading to chronic infections and substantial financial losses for pig farmers. As a result, governments and veterinary authorities in major pork-producing countries such as China, the United States, and countries in the European Union have emphasized vaccination as a critical component of disease control programs. Additionally, rising global pork consumption is pressuring producers to maintain healthier herds and ensure consistent productivity, further boosting demand for effective PRRS vaccines. Technological advancements in vaccine formulation—such as the development of region-specific or genotype-specific modified live vaccines (MLVs)—have improved vaccine efficacy, making immunization a more reliable and widely accepted preventive measure. Moreover, increasing biosecurity awareness and the integration of vaccination into herd health management systems are reinforcing the growth of the PRRS vaccine market globally.
Despite its importance, the PRRS vaccine market faces several challenges that limit its effectiveness and adoption in certain regions. One of the primary issues is the virus's high genetic variability, which complicates the development of universally effective vaccines. The presence of multiple genotypes and frequent mutations means that vaccine strains may not provide cross-protection against all circulating variants, leading to inconsistent results and partial immunity in vaccinated herds. Additionally, modified live vaccines (MLVs), while generally more effective than inactivated ones, carry risks of reversion to virulence or recombination with field strains, which raises safety concerns among producers and regulatory bodies. In developing regions, limited access to veterinary services, cold chain logistics, and affordability issues further hinder the widespread adoption of PRRS vaccination programs. Moreover, there remains a lack of standardized vaccination protocols across countries, and vaccine performance can vary depending on farm conditions, pig genetics, and co-infections with other pathogens. These factors make disease management complex and can reduce confidence in vaccination strategies. Overcoming these challenges requires continued investment in research and development of next-generation vaccines, improved diagnostic tools for strain identification, and stronger government support for vaccination campaigns and swine health education.
This report studies the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine total production and demand, 2021-2032, (K Dose)
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine total production value, 2021-2032, (USD Million)
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine domestic production, consumption, key domestic manufacturers and share
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include China Animal Husbandry Co., Ltd., Boehringer Ingelheim, MSD Animal Health, Sinopharm Animal Health, Ceva, Ruipu Biological, Qilu Animal Health, Dahuanong, CAVAC, Komipharm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market, Segmentation by Type:
Live vaccines
Inactivated vaccines
Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market, Segmentation by Application:
Government bidding
Market sales
Companies Profiled:
China Animal Husbandry Co., Ltd.
Boehringer Ingelheim
MSD Animal Health
Sinopharm Animal Health
Ceva
Ruipu Biological
Qilu Animal Health
Dahuanong
CAVAC
Komipharm
Agrovet
Bioveta
Jinyu
Phibro Animal Health
Tiankang
Zoetis
Yongshun Biological
Pulike Biological
Key Questions Answered:
1. How big is the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market?
2. What is the demand of the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market?
3. What is the year over year growth of the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market?
4. What is the production and production value of the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market?
5. Who are the key producers in the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market?
6. What are the growth factors driving the market demand?
Table of Contents
149 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Manufacturers Competitive Analysis
- 4 United States VS China VS Rest of the World
- 5 Market Analysis by Type
- 6 Market Analysis by Application
- 7 Company Profiles
- 8 Industry Chain Analysis
- 9 Research Findings and Conclusion
- 10 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
